Metformina + Sitagliptina Sandoz Farmacêutica

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metformina + Sitagliptina Sandoz Farmacêutica, is a Biguanide/DPP-4 inhibitor combination presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control. GNH USA supplies Metformina + Sitagliptina Sandoz Farmacêutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina is indicated for management of type 2 diabetes mellitus, targeting hyperglycaemia through complementary mechanisms.

- Type 2 diabetes mellitus: improves overall glycaemic control when diet, exercise and other agents are insufficient. - Adjunct to diet and exercise: helps patients achieve target HbA1c levels. - Combination therapy: provides additional glucose lowering when used with other antidiabetic agents.

Metformina + Sitagliptina may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhoea: loose stools, often transient. - Abdominal discomfort: cramping or bloating. - Headache: mild to moderate intensity. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes. - Renal impairment: worsening kidney function.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

- Renal function monitoring: assess creatinine clearance before and during treatment. - Hepatic function monitoring: check liver enzymes periodically. - Risk of lactic acidosis: avoid in patients with severe heart failure or hypoxia. - Caution in elderly: dose adjustments may be needed due to reduced renal clearance. - Contraindicated in severe renal impairment: do not use when eGFR <30 mL/min/1.73 m². - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Metformina + Sitagliptina can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Concomitant use with insulin or sulfonylureas: increased risk of hypoglycaemia. - Use with iodinated contrast agents: may precipitate acute renal failure, especially with metformin. - Severe renal impairment: metformin accumulation leading to lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides): may affect renal clearance of metformin. - ACE inhibitors or ARBs: can influence renal function and potassium levels. - NSAIDs: may reduce renal perfusion, increasing metformin exposure.